Success Stories: Engineering Smarter Medicine: EB2-NIW Approved for Expert in Controlled-Release Drug Delivery

Case Summary:

We are proud to share the EB2-NIW (National Interest Waiver) approval for a dedicated pharmaceutical technology researcher from Syria whose work is advancing how medications are formulated, delivered, and absorbed. With a focus on chronic disease management, his innovations in controlled-release drug delivery systems (CRDDSs) are helping transform treatment approaches for patients across the globe.

Improving Lives Through Targeted Therapy

The client’s proposed endeavor focuses on developing next-generation CRDDSs—pharmaceutical systems that release drugs over time at controlled rates. These platforms are particularly vital for improving medication efficacy and patient compliance in the treatment of chronic conditions such as diabetes, hypertension, and cardiovascular disease. His work integrates botanical materials into drug matrices, offering low-cost, biocompatible alternatives to synthetic excipients.

Currently engaged in academic research, the client plans to continue his scientific contributions in the U.S. by collaborating with leading pharmaceutical institutions to explore liposomal systems and stimuli-responsive materials for enhanced drug release.

Recognition Through Peer Validation and Global Reach

The client’s contributions have been published in 28 peer-reviewed journals and 2 peer-reviewed conference papers, with a citation count exceeding 300. His work is frequently referenced by peers across disciplines, and at least two of his papers are ranked among the top 10–20% most cited in the field of Pharmacology & Toxicology for their respective years. His widely cited article on the use of Hibiscus rosa-sinensis mucilage as a natural polymer for matrix tablets exemplifies his leadership in sustainable pharmaceutical design.

He has also performed peer review for notable journals such as the Journal of Experimental Pharmacology, which recognizes only accomplished researchers for such roles.

Recommendations from Field Leaders

In support of the petition, respected researchers offered strong endorsements. One recommender from the University of Tennessee wrote:

“Through his work, [client] implemented a plant-based polymer to replace synthetic polymers during the development of controlled-release drug delivery systems… His work introduced cost-effective, yet efficient pharmaceutical products and treatment options, which collectively save Americans trillions of dollars”.

Another recommender noted his contributions to research combating antimicrobial resistance through natural plant extracts, adding:

“His research is essential to patients and the medical professionals who treat them, which in turn demonstrates the undeniable value of his research in his field and to the nation.”

Demonstrating National Importance

This researcher’s focus on CRDDSs aligns directly with U.S. public health priorities and cost-efficiency goals. By proposing plant-based solutions and improving the delivery of poorly soluble drugs, his work supports initiatives to address the treatment of chronic conditions affecting over 130 million Americans. Moreover, his methods reduce the risk of adverse drug reactions and increase therapeutic efficiency, critical components in modern healthcare optimization.

A Strategic and Well-Earned Approval

His petition demonstrates strong evidence of merit and national benefit, emphasizing his successful research record, consistent citations, peer-reviewed publications, and the national relevance of his CRDDS innovations.

We celebrate clients whose work directly improves public health and pharmaceutical innovation. This success story exemplifies how research rooted in scientific rigor and real-world application can serve the national interest—and how immigration pathways like the EB2-NIW can help make it possible.